UC tumours may be inherently less sensitive to the cytostatic cell cycle arrest induced by palbociclib, either due to less dependence on CDK4/6 activity or resistance mechanisms from other pathway members that are less evident in breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.